Reunion Neuroscience's Q4 And Full Year 2023 Financial Results, To Close Take-Private Deal In Q3
Reunion Neuroscience's Q4 And Full Year 2023 Financial Results, To Close Take-Private Deal In Q3
Reunion Neuroscience 的 2023 年第四季度和全年財務業績，將在第三季度完成私有化交易
Clinical-stage psychedelics firm Reunion Neuroscience Inc. (NASDAQ:REUN) reported fiscal results for the fourth quarter and year ended March 31 plus corporate updates.
臨床階段的迷幻藥公司 留尼旺神經科學公司 納斯達克股票代碼：REUN）公佈了該年度的財報截至3月31日的第四季度和年度以及公司最新消息。
Here's a breakdown of the report:
以下是報告的細目：
Cash and cash equivalents of $20.9 (CA$27.7) million as of March 31, compared to $48 million held on the same date in 2022.
R&D expenses of $3.3 and $9.8 million for the three and twelve-month periods, compared to $1.7 and $5.3 million for the same periods in 2022.
G&A expenses of $3 and $9.8 million for the three and twelve-month periods ended March 31, 2023 compared to $2.3 and $8.3 million for the same periods in 2022.
Cash used in...
現金和現金等價物 截至3月31日，爲2,090萬美元（合2770萬加元），而2022年同期的持有量爲4,800萬美元。
研發費用 三個月...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。